Autolus Therapeutics (NASDAQ:AUTL) Stock Price Down 4.6% – What’s Next?

Autolus Therapeutics plc (NASDAQ:AUTL)’s stock price dropped 4.6% during mid-day trading on Tuesday . The stock traded as low as $2.16 and last traded at $2.16. Approximately 234,556 shares traded hands during mid-day trading, a decline of 78% from the average daily volume of 1,070,384 shares. The stock had previously closed at $2.26.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on AUTL shares. The Goldman Sachs Group upgraded Autolus Therapeutics from a “neutral” rating to a “buy” rating and increased their price target for the company from $7.00 to $7.60 in a research note on Monday, November 18th. Needham & Company LLC reiterated a “buy” rating and set a $10.00 target price on shares of Autolus Therapeutics in a research note on Monday, January 13th. Finally, Redburn Atlantic upgraded Autolus Therapeutics from a “neutral” rating to a “buy” rating and set a $13.00 price target for the company in a research note on Friday, November 15th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $10.40.

Autolus Therapeutics Trading Up 0.1 %

The firm has a market cap of $569.96 million, a P/E ratio of -1.76 and a beta of 2.05. The company’s 50-day moving average is $2.55 and its two-hundred day moving average is $3.47.

Autolus Therapeutics (NASDAQ:AUTL) last posted its earnings results on Tuesday, November 12th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.21) by ($0.10). During the same period in the previous year, the firm posted ($0.26) earnings per share. Research analysts anticipate that Autolus Therapeutics plc will post -0.94 EPS for the current fiscal year.

Hedge Funds Weigh In On Autolus Therapeutics

A number of hedge funds have recently modified their holdings of AUTL. ProShare Advisors LLC bought a new stake in shares of Autolus Therapeutics during the second quarter valued at approximately $43,000. Millennium Management LLC lifted its holdings in Autolus Therapeutics by 113.7% during the second quarter. Millennium Management LLC now owns 813,031 shares of the company’s stock valued at $2,829,000 after purchasing an additional 432,503 shares in the last quarter. Herbst Group LLC purchased a new stake in Autolus Therapeutics in the 3rd quarter worth $91,000. Exchange Traded Concepts LLC lifted its holdings in Autolus Therapeutics by 9.8% in the 3rd quarter. Exchange Traded Concepts LLC now owns 41,866 shares of the company’s stock worth $152,000 after purchasing an additional 3,740 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. boosted its position in shares of Autolus Therapeutics by 63.8% during the third quarter. China Universal Asset Management Co. Ltd. now owns 38,393 shares of the company’s stock worth $139,000 after acquiring an additional 14,959 shares during the last quarter. Hedge funds and other institutional investors own 72.83% of the company’s stock.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.